Skip to content

EpCAM-CART in the treatment of recurrence hepatocelluar carcinima

EpCAM-CART in the treatment of recurrence hepatocelluar carcinima

Status
Recruiting
Phases
Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-OIC-17012137
Enrollment
Unknown
Registered
2017-07-25
Start date
2017-07-01
Completion date
Unknown
Last updated
2017-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Recurrence Hepatocellular carcinoma

Interventions

Treatment group:EpCAM CART

Sponsors

West China Hospital, Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: Patients should meet the following criteria to participate in the experiment: 1. have signed informed consent; 2. aged 18 to 75 years male and female; 3. hepatocellular carcinoma recurrence after resection or liver transplantation, no radical resection indications, only through interventional treatment of patients; 4. after resection of postoperative pathology immunohistochemistry confirmed pathologic diagnosis of hepatocellular carcinoma tumor immunohistochemistry suggestive EpCAM (+), adjacent tissue suggestive EpCAM (-); 5. Liver function child A level, before the group of conventional blood tips white blood cell count within the normal range, coagulation function is normal; 6. tumor characteristics can meet any of the following conditions: (1) postoperative liver recurrence to meet BCLC B, (more than a single greater than 5cm, 2-3 more than 3cm standard), may or may not be associated with distant metastasis; (2) patients are reluctant to continue surgery; (3) diffuse liver cancer.

Exclusion criteria

Exclusion criteria: Patients may be excluded from this study if they meet one of the following criteria: 1. with other malignancies; 2. patients are using antineoplastic agents and any other research drugs within 2 weeks of the same period; 3. patients with central nervous system Disease, mental illness, unstable angina, congestive heart failure, severe arrhythmia or other uncontrollable serious illness; 4. patient history of drug or similar structural allergy; 5. pregnancy, breastfeeding or urine pregnancy test Positive; 6. baseline examination of serious infection, bleeding, liver dysfunction or other postoperative complications and life-threatening.

Design outcomes

Primary

MeasureTime frame
objective remission rate;

Countries

China

Contacts

Public ContactJiayin Yang

West China Hospital, Sichuan University

docjackyang@163.com+86 18980602047

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026